Femtosecond laser-assisted cataract surgery

Lingmin He, Katrina Sheehy, William W Culbertson

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Purpose of review: In 2010, the US Food and Drug Administration (FDA) cleared femtosecond laser systems for cataract surgery. Available in 2011, this technology has the potential to significantly impact cataract surgery. Recent findings: Femtosecond lasers offer surgeons the ability to make very precise cuts in a targeted area without damaging the surrounding tissues. This technology has already dramatically changed refractive surgery and is poised to do the same for cataract surgery. Three companies, OptiMedica, LenSx (acquired by Alcon in September 2010), and LensAR, in different stages of FDA clearance, are developing femtosecond laser systems for cataract surgery. These systems will create the initial corneal incisions, capsulotomy, and also fragment the lens. Summary: This article outlines the advantages of femtosecond laser cataract surgery and provides an initial comparison of the LensAR, LenSx/Alcon, and OptiMedica systems and early clinical results.

Original languageEnglish
Pages (from-to)43-52
Number of pages10
JournalCurrent Opinion in Ophthalmology
Volume22
Issue number1
DOIs
StatePublished - Jan 1 2011

Fingerprint

Cataract
Lasers
United States Food and Drug Administration
Technology
Refractive Surgical Procedures
Laser Therapy
Lenses

Keywords

  • Capsulotomy
  • Femtosecond
  • Fragmentation
  • Laser cataract surgery
  • Optical coherence tomography
  • Refractive cataract surgery purpose of review: in 2010

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Femtosecond laser-assisted cataract surgery. / He, Lingmin; Sheehy, Katrina; Culbertson, William W.

In: Current Opinion in Ophthalmology, Vol. 22, No. 1, 01.01.2011, p. 43-52.

Research output: Contribution to journalArticle

He, Lingmin ; Sheehy, Katrina ; Culbertson, William W. / Femtosecond laser-assisted cataract surgery. In: Current Opinion in Ophthalmology. 2011 ; Vol. 22, No. 1. pp. 43-52.
@article{f6c31d405f2a4d2e9d6a735c8d59e8dd,
title = "Femtosecond laser-assisted cataract surgery",
abstract = "Purpose of review: In 2010, the US Food and Drug Administration (FDA) cleared femtosecond laser systems for cataract surgery. Available in 2011, this technology has the potential to significantly impact cataract surgery. Recent findings: Femtosecond lasers offer surgeons the ability to make very precise cuts in a targeted area without damaging the surrounding tissues. This technology has already dramatically changed refractive surgery and is poised to do the same for cataract surgery. Three companies, OptiMedica, LenSx (acquired by Alcon in September 2010), and LensAR, in different stages of FDA clearance, are developing femtosecond laser systems for cataract surgery. These systems will create the initial corneal incisions, capsulotomy, and also fragment the lens. Summary: This article outlines the advantages of femtosecond laser cataract surgery and provides an initial comparison of the LensAR, LenSx/Alcon, and OptiMedica systems and early clinical results.",
keywords = "Capsulotomy, Femtosecond, Fragmentation, Laser cataract surgery, Optical coherence tomography, Refractive cataract surgery purpose of review: in 2010",
author = "Lingmin He and Katrina Sheehy and Culbertson, {William W}",
year = "2011",
month = "1",
day = "1",
doi = "10.1097/ICU.0b013e3283414f76",
language = "English",
volume = "22",
pages = "43--52",
journal = "Current Opinion in Ophthalmology",
issn = "1040-8738",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Femtosecond laser-assisted cataract surgery

AU - He, Lingmin

AU - Sheehy, Katrina

AU - Culbertson, William W

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Purpose of review: In 2010, the US Food and Drug Administration (FDA) cleared femtosecond laser systems for cataract surgery. Available in 2011, this technology has the potential to significantly impact cataract surgery. Recent findings: Femtosecond lasers offer surgeons the ability to make very precise cuts in a targeted area without damaging the surrounding tissues. This technology has already dramatically changed refractive surgery and is poised to do the same for cataract surgery. Three companies, OptiMedica, LenSx (acquired by Alcon in September 2010), and LensAR, in different stages of FDA clearance, are developing femtosecond laser systems for cataract surgery. These systems will create the initial corneal incisions, capsulotomy, and also fragment the lens. Summary: This article outlines the advantages of femtosecond laser cataract surgery and provides an initial comparison of the LensAR, LenSx/Alcon, and OptiMedica systems and early clinical results.

AB - Purpose of review: In 2010, the US Food and Drug Administration (FDA) cleared femtosecond laser systems for cataract surgery. Available in 2011, this technology has the potential to significantly impact cataract surgery. Recent findings: Femtosecond lasers offer surgeons the ability to make very precise cuts in a targeted area without damaging the surrounding tissues. This technology has already dramatically changed refractive surgery and is poised to do the same for cataract surgery. Three companies, OptiMedica, LenSx (acquired by Alcon in September 2010), and LensAR, in different stages of FDA clearance, are developing femtosecond laser systems for cataract surgery. These systems will create the initial corneal incisions, capsulotomy, and also fragment the lens. Summary: This article outlines the advantages of femtosecond laser cataract surgery and provides an initial comparison of the LensAR, LenSx/Alcon, and OptiMedica systems and early clinical results.

KW - Capsulotomy

KW - Femtosecond

KW - Fragmentation

KW - Laser cataract surgery

KW - Optical coherence tomography

KW - Refractive cataract surgery purpose of review: in 2010

UR - http://www.scopus.com/inward/record.url?scp=79955048513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955048513&partnerID=8YFLogxK

U2 - 10.1097/ICU.0b013e3283414f76

DO - 10.1097/ICU.0b013e3283414f76

M3 - Article

C2 - 21150606

AN - SCOPUS:79955048513

VL - 22

SP - 43

EP - 52

JO - Current Opinion in Ophthalmology

JF - Current Opinion in Ophthalmology

SN - 1040-8738

IS - 1

ER -